Botanix Pharmaceuticals (ASX:BOT) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 1985. Start your Free Trial

What is Botanix Pharmaceuticals COGS-to-Revenue?

Botanix Pharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was A$0.38 Mil.

Botanix Pharmaceuticals's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Botanix Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 was N/A%.

Botanix Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Botanix Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Botanix Pharmaceuticals COGS-to-Revenue Chart

Botanix Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

Botanix Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	0.89	-	-

Botanix Pharmaceuticals COGS-to-Revenue Calculation

Botanix Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.103
	=	0.00

Botanix Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0.378
	=	0.00

Botanix Pharmaceuticals (ASX:BOT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Botanix Pharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0.378
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Botanix Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Botanix Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Botanix Pharmaceuticals (ASX:BOT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Botanix Pharmaceuticals Ltd (ASX:BOT) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

BXPHF:USA

Address

661 Newcastle Street, D2, LEEDERVILLE, WA, AUS, 6007

Website

https://www.botanixpharma.com

Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

Botanix Pharmaceuticals (ASX:BOT) Headlines

No Headlines